INTRA CELLULAR THERAPIES INC's ticker is ITCI and the CUSIP is 46116X101. A total of 211 filers reported holding INTRA CELLULAR THERAPIES INC in Q4 2021. The put-call ratio across all filers is 0.45 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2022 | $1,493,000 | -58.6% | 32,071 | -49.3% | 0.01% | -65.7% |
| Q2 2022 | $3,608,000 | -39.8% | 63,201 | -35.5% | 0.04% | -35.2% |
| Q1 2022 | $5,992,000 | +427.0% | 97,925 | +351.0% | 0.05% | +440.0% |
| Q4 2021 | $1,137,000 | -45.4% | 21,715 | -83.5% | 0.01% | -94.7% |
| Q3 2017 | $2,083,000 | +313.3% | 131,980 | +325.9% | 0.19% | +272.5% |
| Q1 2017 | $504,000 | +9.6% | 30,989 | +161.0% | 0.05% | -50.5% |
| Q2 2016 | $460,000 | – | 11,871 | – | 0.10% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| DCF Advisers, LLC | 359,000 | $18,790,000 | 7.62% |
| Velan Capital Investment Management LP | 150,000 | $7,851,000 | 6.09% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 195,000 | $10,206,000 | 4.14% |
| Vantage Consulting Group Inc | 226,670 | $11,864,000 | 3.19% |
| Vahanian & Associates Financial Planning Inc. | 71,742 | $3,755,000 | 3.03% |
| Nicholas Investment Partners, LP | 652,886 | $34,172,000 | 2.16% |
| COOPER/HAIMS ADVISORS, LLC | 61,116 | $3,199,000 | 1.97% |
| Bellevue Group AG | 3,628,919 | $189,938,000 | 1.96% |
| WASATCH ADVISORS LP | 8,235,171 | $431,029,000 | 1.76% |
| Quantum Private Wealth, LLC | 77,622 | $4,062,000 | 1.54% |